Literature DB >> 1745007

Interleukin-1 beta stimulates human mesangial cells to synthesize and release interleukins-6 and -8.

F Abbott1, J J Ryan, M Ceska, K Matsushima, C E Sarraf, A J Rees.   

Abstract

Interleukin-1 beta (IL-1 beta) and tumor necrosis factor (TNF) have been reported to stimulate human mesangial cells (HMC) to proliferate and synthesize eicosanoids. We have examined whether they also induce HMC to release cytokines. In this study we show that both IL-1 and TNF stimulate HMC to release IL-6 and IL-8. Cycling and quiescent HMC were stimulated with various concentrations of either recombinant IL-1 beta or TNF for 1 to 24 hours. IL-1 beta at doses as low as 6 pg/ml stimulated mesangial cells to synthesize mRNA for both IL-6 and IL-8 as assessed by Northern analysis; mRNA for tubulin remained constant, which demonstrated a specific increase in mRNA. Secretion of IL-6 and IL-8 into the culture medium increased (4.5 to 18 ng/ml and 4 to 40 ng/ml, respectively) measured by ELISAs. TNF had similar effects but only in high concentrations (greater than 100 ng/ml). IL-1 beta did not stimulate cells to proliferate, as measured by 3H thymidine incorporation. TNF caused proliferation but only in concentrations over 100 ng/ml. We conclude that IL-1 beta is a potent stimulator of human mesangial cell production of IL-6 and IL-8, both of which may influence injury in nephritis. TNF also stimulates mesangial cells but only in pharmacological doses.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1745007     DOI: 10.1038/ki.1991.250

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  26 in total

Review 1.  Novel therapeutic approaches for progressive renal disorders by targeting glomerular component mesangial and endothelial cells.

Authors:  Yohei Maeshima
Journal:  Clin Exp Nephrol       Date:  2005-12       Impact factor: 2.801

2.  Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo.

Authors:  Y Maeshima; N Kashihara; T Yasuda; H Sugiyama; T Sekikawa; K Okamoto; K Kanao; Y Watanabe; Y S Kanwar; H Makino
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

3.  Role of interleukin-1 in mesangial cell proliferation and matrix deposition in experimental mesangioproliferative nephritis.

Authors:  G H Tesch; H Y Lan; R C Atkins; D J Nikolic-Paterson
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

Review 4.  Inflammation and glomerular injury.

Authors:  A Benigni; G Remuzzi
Journal:  Springer Semin Immunopathol       Date:  1994

5.  Mesangial cell apoptosis: the major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis.

Authors:  A J Baker; A Mooney; J Hughes; D Lombardi; R J Johnson; J Savill
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

6.  A granulocyte inhibitory protein overexpressed in chronic renal disease regulates expression of interleukin 6 and interleukin 8.

Authors:  R Ziesche; M Roth; E Papakonstantinou; M Nauck; W H Hörl; M Kashgarian; L H Block
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

7.  Cell-specific regulation of type II phospholipase A2 expression in rat mesangial cells.

Authors:  M Konieczkowski; J R Sedor
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

8.  Mesangial cell-matrix interactions. Effects on mesangial cell growth and cytokine secretion.

Authors:  C Ruef; M Kashgarian; D L Coleman
Journal:  Am J Pathol       Date:  1992-08       Impact factor: 4.307

Review 9.  The inflammatory function of renal glomerular mesangial cells and their interaction with the cellular immune system.

Authors:  H H Radeke; K Resch
Journal:  Clin Investig       Date:  1992-09

10.  Interferon-inducible protein-10 is highly expressed in rats with experimental nephrosis.

Authors:  M Gómez-Chiarri; A Ortiz; S González-Cuadrado; D Serón; S N Emancipator; T A Hamilton; A Barat; J J Plaza; E González; J Egido
Journal:  Am J Pathol       Date:  1996-01       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.